Arcutis Biotherapeutics, Inc. (ARQT) P/E Ratio History
Fairly ValuedTrading at 116.9x, near 5Y avg of 125.0x · 0th percentile · In line with own history · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Arcutis Biotherapeutics, Inc. (ARQT) trades at a price-to-earnings ratio of 116.9x, with a stock price of $25.55 and trailing twelve-month earnings per share of $0.22.
The current P/E is roughly in line with its 5-year average of 125.0x. Over the past five years, ARQT's P/E has ranged from a low of 124.3x to a high of 125.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, ARQT trades at a 375% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, ARQT commands a significant premium over the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARQT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ARQT Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ARQT P/E vs Peers
Dermatology & Aesthetic Drugs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 7.1Lowest | 0.69Best | +817%Best | |
| $2B | 11.1 | - | +8% | |
| $191B | 40.6 | 4.91 | -51% | |
| $124B | 26.3 | - | +49% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ARQT Historical P/E Data (2026–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $26.43 | $0.21 | 124.3x | -1% |
| FY2026 Q2 | - | $26.22 | $0.21 | 125.8x | +1% |
Average P/E for displayed period: 125.0x
ARQT Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ARQT — Frequently Asked Questions
Quick answers to the most common questions about buying ARQT stock.
What is ARQT's P/E ratio?
Arcutis Biotherapeutics, Inc. (ARQT) trailing twelve-month P/E ratio is 116.9x, based on TTM diluted EPS of $0.22. The 5-year average P/E is 125.0x and the historical range spans 124.3x to 125.8x.
Is ARQT stock overvalued or undervalued?
ARQT trades at 116.9x P/E, near its 5-year average of 125.0x. The 0th percentile ranking within the 124.3x–125.8x historical range places valuation within normal bounds.
Is ARQT stock expensive?
ARQT is fairly valued relative to its own history. The current P/E of 116.9x is near the 5-year average of 125.0x (0th percentile of historical range).
What is ARQT's historical P/E range?
Over the past 5 years, ARQT's P/E ratio has ranged from 124.3x to 125.8x, with a median of 125.8x and an average of 125.0x. The current P/E of 116.9x places the stock at the 0th percentile of this range. Full historical data spans 2026–2026.
How does ARQT's P/E compare to the S&P 500?
ARQT trades at 116.9x P/E versus the S&P 500 median of 21.8x. The 436% premium to the market typically reflects higher expected earnings growth or quality.
How does ARQT's valuation compare to Healthcare peers?
Arcutis Biotherapeutics, Inc. P/E of 116.9x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ARQT's PEG ratio?
ARQT PEG ratio is N/A, based on a P/E of 116.9x and EPS growth of 88.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ARQT's earnings yield?
ARQT earnings yield is 0.86%, the inverse of its 116.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.